- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.11. | Insmed receives EC approval for Brinsupri to treat NCFB | ||
| 18.11. | Johnson & Johnson to acquire Halda Therapeutics for $3.05bn | ||
| 17.11. | Sofinnova closes €650m healthcare fund for early-stage ventures | ||
| 14.11. | Eisai and Biogen report Leqembi's MHRA approval for Alzheimer's | ||
| 13.11. | BostonGene and Kyoto University link on oesophageal cancer drug | ||
| 12.11. | March Bio's MB-105 gains FDA RMAT for CD5+ T-cell lymphoma | ||
| 11.11. | Novartis opens California site for RLT manufacturing | ||
| 10.11. | SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases | ||
| 07.11. | Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz | ||
| 06.11. | Leukogene Therapeutics gains FDA ODD status for M2T-CD33 | ||
| 05.11. | AmacaThera and Pacira sign agreement for AMT-143 | ||
| 04.11. | CNX Therapeutics expands CNS portfolio with Sativex acquisition | ||
| 03.11. | Calluna secures FDA orphan drug designation for CAL101 in IPF | ||
| 31.10. | Arcutis introduces roflumilast cream for paediatric atopic dermatitis | ||
| 30.10. | Samsung Bioepis to acquire commercial rights for Byooviz in Europe | ||
| 29.10. | Myrio Therapeutics announces partnership for immunotherapy development | ||
| 28.10. | Hovione finalises $100m investment for East Windsor site expansion in US | ||
| 27.10. | Biogen acquires global rights to Vanqua C5aR1 antagonist | ||
| 24.10. | Naobios and TMIMS to develop new live mpox vaccine | ||
| 23.10. | Boehringer's Jascayd gains NMPA approval for idiopathic pulmonary fibrosis | ||
| 22.10. | Portal Therapeutics receives FDA orphan, fast track designations for PORT-77 | ||
| 21.10. | Citius Oncology finalises McKesson deal for Lymphir distribution | ||
| 17.10. | Tempus partners with Whitehawk on oncology research | ||
| 16.10. | FDA accepts Chiesi triple combination inhaler application for asthma | ||
| 15.10. | iQure, University of Padova collaborate to investigate iQ-007 mechanism |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .